Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571306 | 1.00 | BTK (0.48) | BTKKDM1AGAAMAOBNFKB1 | |
| SCHEMBL31601158 | 1.00 | BTK (0.48) | BTKKDM1AGAAMAOBNFKB1 | |
| SCHEMBL30473209 | 0.91 | BTK (0.51) | BTKKDM1AGAAMAOBNFKB1 | |
| SCHEMBL31601203 | 0.87 | BTK (0.37) | BTKKDM1AGAAMAOBNFKB1 | |
| SCHEMBL15777845 | 0.82 | BTK (0.61) | BTKKDM1AGAAMAOBNFKB1 | |
| SCHEMBL31601393 | 0.82 | KDM1A (0.40) | BTKKDM1AGAAMAOBNFKB1 | |
| SCHEMBL31601395 | 0.82 | KDM1A (0.40) | BTKKDM1AGAAMAOBNFKB1 | |
| SCHEMBL4479750 | 0.82 | BTK (0.39) | BTKKDM1AGAAMAOBNFKB1 | |
| SCHEMBL30473133 | 0.82 | BTK (0.39) | BTKKDM1AGAAMAOBNFKB1 | |
| SCHEMBL4479752 | 0.82 | BTK (0.39) | BTKKDM1AGAAMAOBNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117915-B2 | Antibacterial aminoglycoside analogs | Cipla USA, Inc. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11117915-B2 | Antibacterial aminoglycoside analogs | Cipla USA, Inc. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2020-10-08 | — | — | US | disclosed |
| EP-3150617-B1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | CIPLA USA INC (US) | 2020-04-08 | — | — | EP | disclosed |
| US-RE47741-E1 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2019-11-26 | — | — | US | disclosed |
| US-RE47741-E1 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2019-11-26 | — | — | US | disclosed |
| US-9688711-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688711-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| EP-3150617-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Achaogen, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20120196791-A1 | COMBINATION THERAPIES USING ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120184501-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120172332-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120165282-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120135948-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135945-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135946-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20110288041-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20100099661-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099661-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135948-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | BTK 4109/4885KDM1A 3770/4885GAA 200/4885 |
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | BTK 2661/4885KDM1A 3349/4885GAA 253/4885 |
| US-20120135946-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | BTK 3798/4885KDM1A 3651/4885GAA 148/4885 |
| US-20100099661-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | BTK 2661/4885KDM1A 3349/4885GAA 253/4885 |
| US-20120172332-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | BTK 3761/4885KDM1A 3464/4885GAA 168/4885 |
| US-20120135945-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | BTK 3730/4885KDM1A 3605/4885GAA 140/4885 |
| US-20110288041-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | BTK 3761/4885KDM1A 3464/4885GAA 168/4885 |
| US-20120196791-A1 | COMBINATION THERAPIES USING ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | PIGS, PIGO, NPEPPS | BTK 2592/4885KDM1A 4694/4885GAA 63/4885 |
| US-20120184501-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | BTK 4047/4885KDM1A 3377/4885GAA 159/4885 |
| US-11117915-B2 | Antibacterial aminoglycoside analogs | MRPL21, MRPL9, NQO2 | BTK 2661/4885KDM1A 3349/4885GAA 253/4885 |
| US-20120165282-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, QARS1, NQO2 | BTK 4296/4885KDM1A 3440/4885GAA 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.